Core Viewpoint - The company *ST Changyao is under investigation by the China Securities Regulatory Commission for suspected false reporting of financial data, which poses significant risks of major violations, non-compliance with restructuring, and forced delisting due to financial issues [1] Financial Performance - The company's net assets were reported at -433 million yuan at the end of 2024 and -643 million yuan by the end of the third quarter of 2025 [1] - Revenue has significantly declined from 1.615 billion yuan in 2022 to 112 million yuan in 2024 [1] Legal and Financial Risks - The company is involved in 151 lawsuits and arbitrations, with a total amount in dispute of 1.93 billion yuan [1] - There are risks associated with overdue large interest-bearing debts, frozen accounts, and tax arrears from subsidiaries [1]
*ST长药：立案调查进展披露，存多项退市及经营风险
Xin Lang Cai Jing·2025-12-22 09:22